2017年9月8日 · CD30 ligand (CD30L, also known as TNFSF8 or CD153) is a membrane-bound cytokine with sequence homology to other members of the tumor necrosis factor (TNF) family. 4 CD30L can be detected in...

Increased CD30L expression was found on mast cells within HD tumors and preclinical and clinical studies with compounds targeting the CD30/ CD30L system in HD and ALCL demonstrated therapeutic benefit.

2024年11月26日 · Results: Analysis of several scRNA-seq datasets from skin lesions of AD patients showed that transcripts for CD30 or CD30L were found expressed with OX40 or OX40L in the primary T cell populations that also expressed mRNA for IL13 and/or IL22.

The results suggest that CD30L/CD30 signaling is involved in the development of both OXA- and TNBS-induced colitis and that the modulation of CD30L/CD30 signaling by mAb could be a novel biological therapy for IBD.

The transmembrane receptor CD30 (TNFRSF8) and its ligand CD30L (CD153, TNFSF8) are members of the tumor necrosis factor (TNF) superfamily and display restricted expression in subpopulations of activated T-and B-cells in nonpathologic conditions.

CD30 Ligand is a type II membrane glycoprotein expressed on various immune cells, such as activated T cells, B cells, and macrophages. It plays a role in regulating the growth and activation of malignant cells, particularly in Hodgkin's lymphoma, by interacting with CD30-expressing cells.

In this review we consider the reported biology of CD30L and focus on results from several recent studies that point to an important role for CD30/CD30L interactions in humoral immune responses. Keywords: CD30 ligand, CD30, humoral immunity, immunoglobulin, tumour necrosis factor ligand superfamily.

Successful anti-CD30 antibody-drug conjugate (ADC) therapy for HL, ALCL, and PTCL supports the biological significance of CD30 in these lymphomas. In this review, we discuss the roles of CD30 overexpression and its functions during ATL progression.

2015年2月1日 · CD30L/CD30 signaling promotes two-step antigen-specific CD4 T cell responses. Soluble mCD30-Ig treatment before or even after disease onset ameliorates EAE. The CD30 ligand (CD30L)/CD30 axis plays a critical role in Th1 and Th17 cell differentiation. However, the role in the pathogenesis of central nervous system autoimmunity remains unknown.

In this study, we established an AOM/DSS-induced CAC model with CD30LKO mice to explore the effect of CD30L/CD30 signal transduction on the formation of the intestinal tumor immune microenvironment (TIME) during the development of intestinal tumors.